Avectas nets patent for cell engineering technology

By The Science Advisory Board staff writers

April 8, 2020 -- Avectas has received a patent for its Solupore cell engineering technology.

The U.S. Patent and Trademark Office issued U.S. patent No. 10,612,042, which covers the company's approach for delivering a payload, such as a protein or nucleic acid, across a plasma membrane of a cell.

Avectas is developing the delivery platform designed for the ex vivo manufacture of gene-modified cell therapy products. Its Solupore cell engineering technology is designed to overcome the challenges of manufacturing autologous and allogeneic cellular therapy products.

In March, Avectas announced a collaboration with Vycellix to develop technology for the optimized manufacture of cell and gene therapies. In February, Avectas signed a collaboration agreement with the Centre for Commercialization of Regenerative Medicine in Toronto to bring its Solupore nonviral cell engineering platform into the clinic.

Vycellix, Avectas partner for product development
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter